{"id":"https://openalex.org/W6967207143","doi":"https://doi.org/10.5167/uzh-262336","title":"A targetable type III immune response with increase of IL-17A expressing CD4$^{+}$ T cells is associated with immunotherapy-induced toxicity in melanoma","display_name":"A targetable type III immune response with increase of IL-17A expressing CD4$^{+}$ T cells is associated with immunotherapy-induced toxicity in melanoma","publication_year":2024,"publication_date":"2024-08-29","ids":{"openalex":"https://openalex.org/W6967207143","doi":"https://doi.org/10.5167/uzh-262336"},"language":"en","primary_location":{"id":"pmh:oai:www.zora.uzh.ch:262336","doi":null,"is_oa":true,"landing_page_url":"https://www.zora.uzh.ch/id/eprint/262336/1/1031_Dimitriou_F._et_al._A_targetable_type_III_immune_response_with_increase_of_IL_17A_expressing_CD4T_cells_is_associated_with_immunotherapy_nature_cancer_2024.pdf","pdf_url":"https://www.zora.uzh.ch/id/eprint/262336/1/1031_Dimitriou_F._et_al._A_targetable_type_III_immune_response_with_increase_of_IL_17A_expressing_CD4T_cells_is_associated_with_immunotherapy_nature_cancer_2024.pdf","source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"},"volume":null,"type":"article","indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.zora.uzh.ch/id/eprint/262336/1/1031_Dimitriou_F._et_al._A_targetable_type_III_immune_response_with_increase_of_IL_17A_expressing_CD4T_cells_is_associated_with_immunotherapy_nature_cancer_2024.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5151001306","display_name":"Florentia; https://orcid.org/0000-0003-4529-3372 Dimitriou","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dimitriou, Florentia","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4529-3372","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046436556","display_name":"Phil Fang Cheng","orcid":"https://orcid.org/0000-0003-2940-006X","observed_orcids":["https://orcid.org/0000-0003-2940-006X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cheng, Phil F","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2940-006X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006920216","display_name":"Annalisa Saltari","orcid":"https://orcid.org/0000-0002-8621-4039","observed_orcids":["https://orcid.org/0000-0002-8621-4039"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Saltari, Annalisa","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8621-4039","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029601617","display_name":"Katrin Schaper\u2010Gerhardt","orcid":"https://orcid.org/0000-0002-5318-0039","observed_orcids":["https://orcid.org/0000-0002-5318-0039"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Schaper-Gerhardt, Katrin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042201716","display_name":"Ramon Staeger","orcid":"https://orcid.org/0000-0002-9283-9596","observed_orcids":["https://orcid.org/0000-0002-9283-9596"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Staeger, Ramon","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9283-9596","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035263466","display_name":"Veronika Haunerdinger","orcid":"https://orcid.org/0000-0002-6184-8182","observed_orcids":["https://orcid.org/0000-0002-6184-8182"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Haunerdinger, Veronika","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Sella, Federica","orcid":"https://orcid.org/0000-0002-0805-0905","observed_orcids":["https://orcid.org/0000-0002-0805-0905"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sella, Federica","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0805-0905","affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Tastanova, Aizhan","orcid":"https://orcid.org/0000-0003-1120-5610","observed_orcids":["https://orcid.org/0000-0003-1120-5610"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tastanova, Aizhan","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1120-5610","affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Urban, Christian","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Urban, Christian","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087137618","display_name":"Susanne Dettwiler","orcid":"https://orcid.org/0000-0003-1169-6296","observed_orcids":["https://orcid.org/0000-0003-1169-6296"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dettwiler, Susanne","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1169-6296","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058659054","display_name":"Daniela Mihic\u2010Probst","orcid":"https://orcid.org/0000-0002-2215-9958","observed_orcids":["https://orcid.org/0000-0002-2215-9958"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mihic-Probst, Daniela","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2215-9958","affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Matter, Christian M","orcid":"https://orcid.org/0000-0002-8124-1767","observed_orcids":["https://orcid.org/0000-0002-8124-1767"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matter, Christian M","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8124-1767","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009968141","display_name":"Olivier Alain Michielin","orcid":"https://orcid.org/0000-0003-4926-6355","observed_orcids":["https://orcid.org/0000-0003-4926-6355"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michielin, Olivier","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015081105","display_name":"Ralf Gutzmer","orcid":"https://orcid.org/0000-0001-7921-2820","observed_orcids":["https://orcid.org/0000-0001-7921-2820"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gutzmer, Ralf","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7921-2820","affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Long, Georgina V","orcid":"https://orcid.org/0000-0001-8894-3545","observed_orcids":["https://orcid.org/0000-0001-8894-3545"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Long, Georgina V","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8894-3545","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051595544","display_name":"Burkhard Becher","orcid":"https://orcid.org/0000-0002-1541-7867","observed_orcids":["https://orcid.org/0000-0002-1541-7867"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Becher, Burkhard","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1541-7867","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031480514","display_name":"Mitchell  Paul Levesque","orcid":"https://orcid.org/0000-0001-5902-9420","observed_orcids":["https://orcid.org/0000-0001-5902-9420","https://orcid.org/0000-0002-1830-6265"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Levesque, Mitchell P","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5902-9420","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5151075518","display_name":"Reinhard; https://orcid.org/0000-0002-2279-6906 Dummer","orcid":"https://orcid.org/0000-0002-2279-6906","observed_orcids":["https://orcid.org/0000-0002-2279-6906"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dummer, Reinhard","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2279-6906","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.38939214,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":true,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.847000002861023},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.8889999985694885},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.9599999785423279},{"id":"https://openalex.org/keywords/il-17a","display_name":"IL-17A","score":0.9539999961853027},{"id":"https://openalex.org/keywords/cd4-t-cells","display_name":"CD4+ T cells","score":0.9829999804496765},{"id":"https://openalex.org/keywords/anti-il-17a-therapy","display_name":"anti-IL-17A therapy","score":0.9290000200271606},{"id":"https://openalex.org/keywords/immune-related-myocarditis","display_name":"immune-related myocarditis","score":0.722000002861023},{"id":"https://openalex.org/keywords/immune-mediated-colitis","display_name":"immune-related colitis","score":0.9440000057220459},{"id":"https://openalex.org/keywords/spatial-transcriptomics","display_name":"spatial transcriptomics","score":0.6890000104904175}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7433000206947327},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.7085999846458435},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.6891000270843506},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.6227999925613403},{"id":"https://openalex.org/C13373296","wikidata":"https://www.wikidata.org/wiki/Q421866","display_name":"Chemokine","level":3,"score":0.5196999907493591},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.49320000410079956},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.48980000615119934},{"id":"https://openalex.org/C2775862500","wikidata":"https://www.wikidata.org/wiki/Q2453464","display_name":"Colitis","level":2,"score":0.4659000039100647},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.41530001163482666},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.4009999930858612},{"id":"https://openalex.org/C2781188995","wikidata":"https://www.wikidata.org/wiki/Q6934982","display_name":"Multiplex","level":2,"score":0.3779999911785126},{"id":"https://openalex.org/C553184892","wikidata":"https://www.wikidata.org/wiki/Q1141429","display_name":"Flow cytometry","level":2,"score":0.3675999939441681},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.3522999882698059},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.32030001282691956},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.3093000054359436},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.2953000068664551},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2865999937057495},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.28220000863075256},{"id":"https://openalex.org/C137061746","wikidata":"https://www.wikidata.org/wiki/Q736033","display_name":"Peripheral blood mononuclear cell","level":3,"score":0.27900001406669617},{"id":"https://openalex.org/C2777761686","wikidata":"https://www.wikidata.org/wiki/Q715347","display_name":"Lymphocyte","level":2,"score":0.27730000019073486},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.27320000529289246},{"id":"https://openalex.org/C204232928","wikidata":"https://www.wikidata.org/wiki/Q899285","display_name":"Immunohistochemistry","level":2,"score":0.2685999870300293},{"id":"https://openalex.org/C2992881475","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T lymphocyte","level":3,"score":0.26649999618530273},{"id":"https://openalex.org/C136449434","wikidata":"https://www.wikidata.org/wiki/Q428253","display_name":"Innate immune system","level":3,"score":0.2558000087738037}],"mesh":[],"locations_count":2,"locations":[{"id":"pmh:oai:www.zora.uzh.ch:262336","doi":null,"is_oa":true,"landing_page_url":"https://www.zora.uzh.ch/id/eprint/262336/1/1031_Dimitriou_F._et_al._A_targetable_type_III_immune_response_with_increase_of_IL_17A_expressing_CD4T_cells_is_associated_with_immunotherapy_nature_cancer_2024.pdf","pdf_url":"https://www.zora.uzh.ch/id/eprint/262336/1/1031_Dimitriou_F._et_al._A_targetable_type_III_immune_response_with_increase_of_IL_17A_expressing_CD4T_cells_is_associated_with_immunotherapy_nature_cancer_2024.pdf","source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"},{"id":"doi:10.5167/uzh-262336","doi":"https://doi.org/10.5167/uzh-262336","is_oa":true,"landing_page_url":"https://doi.org/10.5167/uzh-262336","pdf_url":null,"source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":null,"raw_source_name":null,"raw_type":"JournalArticle"}],"best_oa_location":{"id":"pmh:oai:www.zora.uzh.ch:262336","doi":null,"is_oa":true,"landing_page_url":"https://www.zora.uzh.ch/id/eprint/262336/1/1031_Dimitriou_F._et_al._A_targetable_type_III_immune_response_with_increase_of_IL_17A_expressing_CD4T_cells_is_associated_with_immunotherapy_nature_cancer_2024.pdf","pdf_url":"https://www.zora.uzh.ch/id/eprint/262336/1/1031_Dimitriou_F._et_al._A_targetable_type_III_immune_response_with_increase_of_IL_17A_expressing_CD4T_cells_is_associated_with_immunotherapy_nature_cancer_2024.pdf","source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.6634194850921631,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Immune":[0],"checkpoint":[1],"inhibitors":[2],"are":[3],"standard-of-care":[4],"for":[5,148,154],"the":[6,34,58,64,74,79,100,125,131],"treatment":[7],"of":[8,46,60,66,102,124,134],"advanced":[9],"melanoma,":[10],"but":[11],"their":[12],"use":[13],"is":[14],"limited":[15],"by":[16],"immune-related":[17],"adverse":[18,35,75,126,141,156],"events.":[19,127,157],"Proteomic":[20],"analyses":[21],"and":[22,25,32,49,87,94,119,144],"multiplex":[23],"cytokine":[24],"chemokine":[26],"assays":[27],"from":[28],"serum":[29],"at":[30,33,73],"baseline":[31],"event":[36,76,142],"onset":[37,77],"indicated":[38],"aberrant":[39],"T":[40,68,104,138],"cell":[41],"activity":[42],"with":[43,57,70,106,115,122],"differential":[44],"expression":[45,72],"type":[47,135],"I":[48],"III":[50,136],"immune":[51],"signatures.":[52],"This":[53,128],"was":[54,110],"in":[55,63,78,99,112,140],"line":[56],"finding":[59],"an":[61,97],"increase":[62,98],"proportion":[65,101],"CD4$^{+}$":[67,103,137],"cells":[69,105,139],"IL-17A":[71,107],"peripheral":[80],"blood":[81],"using":[82,152],"flow":[83],"cytometry.":[84],"Multiplex":[85],"immunohistochemistry":[86],"spatial":[88],"transcriptomics":[89],"on":[90],"immunotherapy-induced":[91],"skin":[92,120],"rash":[93,121],"colitis":[95,118],"showed":[96],"expression.":[108],"Anti-IL-17A":[109],"administered":[111],"two":[113],"patients":[114],"mild":[116],"myocarditis,":[117],"resolution":[123],"study":[129],"highlights":[130],"potential":[132],"role":[133],"development":[143],"provides":[145],"proof-of-principle":[146],"evidence":[147],"a":[149],"clinical":[150],"trial":[151],"anti-IL-17A":[153],"treating":[155]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2025-10-10T00:00:00"}